Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 1, 2010, Pages 40-47

  Lejeune, Catherine ^a   Dancourt, Vincent ^a   Arveux, Patrick ^a   Bonithon Kopp, Claire ^a   Faivre, Jean ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Colorectal cancer; Cost effectiveness; Markov chains; Mass screening

Indexed keywords

COLORECTAL CANCER; GENERAL POPULATION; INCREMENTAL COST; LEADTIME; MARKOV CHAIN; MARKOV CHAINS; MARKOV MODEL; PARTICIPATION RATE; PURCHASE PRICE; SCREENING TESTS;

COST EFFECTIVENESS; COSTS; MARKOV PROCESSES; SENSITIVITY ANALYSIS; TESTING;

COST BENEFIT ANALYSIS;

GUAIAC; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FRANCE; HIDDEN MARKOV MODEL; HUMAN; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; OCCULT BLOOD; SENSITIVITY ANALYSIS; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOLOGICAL PROCEDURES; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PROBABILITY; SENSITIVITY AND SPECIFICITY;

AGED; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FRANCE; GUAIAC; HUMANS; IMMUNOLOGIC TESTS; INDICATORS AND REAGENTS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

EID: 77949902214     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S026646230999078X     Document Type: Article

References (33)

1. Angell-Andersen E, Tretli S, Coleman MP, et al. Colorectal cancer survival trends in Norway 1958-1997. Eur J Cancer. 2004;40:734-742.
2. Arora G, Mannalithara A, Singh G, et al. Risk of perforation from a colonoscopy in adults: A large population-based study. Gastrointest Endosc. 2009;69:654-664.
3. Berchi C, Bouvier V, Ŕeaud JM, et al. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ. 2003;13:227-238.
4. Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: Results of the EUROCARE-4 study. Lancet Oncol. 2007;8:773-783.
5. Boulin M, Lejeune C, Le Teuff G, et al. Patterns of surveillance practices after curative surgery for colorectal cancer in a French population. Dis Colon Rectum. 2005;48:1890-1899.
6. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481-488.
7. Castiglione G, Zappa M, Grazzini G, et al. Immunochemical vs guaiac faecal occult blood tests in a population- based screening programme for colorectal cancer. Br J Cancer. 1996;74:141-144.
8. Citarda F, Tomaselli G, Capocaccia R, et al. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut. 2001;48:812-815.
9. Clerc L, Jooste V, Lejeune C, et al. Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur J Health Econ. 2008;9:361-367.
10. Consensus Conference. Prevention, screening and management of the colonic cancers. Gastroenterol Clin Biol. 1998;22:S275-S288.
11. Dancourt V, Lejeune C, Lepage C, et al. Comparison of guaiac and immunochemical faecal occult blood tests for detecting colorectal neoplasia in an average-risk population Eur J Cancer. 2008;44:2254-2258.
12. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437-452.
13. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J. 1996;313:275-283
14. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674-1680. (Pubitemid 38736331)
15. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210-214.
16. Gyrd-Hansen D, Sogaard J, Kronborg O. Analysis of screening data: Colorectal cancer. Int J Epidemiol. 1997;26:1172-1181. (Pubitemid 28010434)
17. Gyrd-Hansen D. Fecal occult blood tests. A cost-effectiveness analysis. Int J Technol Assess Health Care. 1998;14:290-301.
18. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472-1477.
19. Jorgensen OD, Kronborg O, Fenger C. The Funen Adenoma Follow-up Study. Incidence and death from colorectal carcinoma in an adenoma surveillance program. Scand J Gastroenterol. 1993;28:869-874.
20. Jouve JL, Remontet L, Dancourt V, et al. Estimation of screening test (Hemoccult R) sensitivity in colorectal cancer mass screening. Br J Cancer. 2001;84:1477-1481.
21. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467-1471.
22. Launoy G, Smith TC, Duffy SW, Bouvier V. Colorectal cancer mass-screening: Estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int J Cancer. 1997;73:220-224.
23. Launoy GD, Bertrand HJ, Berchi C, et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer. 2005;115:493-496. (Pubitemid 40663756)
24. Lejeune C, Arveux P, Dancourt V, et al. A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer. Eur J Cancer Prev. 2003;12:77-84.
25. Lejeune C, Arveux P, Dancourt V, et al. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Technol Assess Health Care. 2004;20:434-439. (Pubitemid 39491490)
26. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422-428.
27. Recommendations on cancer screening in the European Union. Advisory Committee on Cancer Prevention. Eur J Cancer. 2000;36:1473-1478.
28. Shimbo T, Glick HA, Eisenberg JM.Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Assess Health Care. 1994;10:359-375.
29. Stryker SJ, Wolff BG, Culp CE, et al. Natural history of untreated colonic polyps. Gastroenterology. 1987;93:1009-1013.
30. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82-90.
31. Whynes DK, Neilson AR, Walker AR, Hardcastle JD. Faecal occult blood screening for colorectal cancer: Is it cost- effective? Health Econ. 1998;7:21-29.
32. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329:1977-1981.
33. Zappa M, Castiglione G, Paci E, et al. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: The District of Florence experience. Int J Cancer. 2001;92:151-154.